Electronic NDA Requirement Should Be Phased In Over 3 Years, Small Firms Say
Executive Summary
Small pharmaceutical companies favor FDA's proposal to move from paper to electronic filing of regulatory submissions but want a three-year grace period following the agency's issuance of a final rule
You may also be interested in...
FDA’s Technology Plan Will Wound, But Not Kill, Paper Submissions By 2012
FDA is seeking comment on the next steps the agency plans to take under the fourth extension of the Prescription Drug User Fee Act in order to move towards its vision of eliminating paper for the submission and review of all regulatory documents
FDA’s Technology Plan Will Wound, But Not Kill, Paper Submissions By 2012
FDA is seeking comment on the next steps the agency plans to take under the fourth extension of the Prescription Drug User Fee Act in order to move towards its vision of eliminating paper for the submission and review of all regulatory documents
User Fee Hike Will Give Sponsors Clarity On Label, Postmarketing Discussions
As part of its recommendations for the renewal of the user fee program, FDA is proposing refinements to its "74-day letters" to give sponsors a more detailed schedule of how the application review will proceed